£520.00

The 2023-2028 Outlook for Respiratory Disorder Treatments in the United States

Subjects

Price data last checked 18 day(s) ago - will refresh soon

View at Amazon

We'll watch every seller, every day. One email when your price arrives.

It has never been this cheap. We have no record of a lower price.

£520 today · cheaper than every other day in the last 3 months

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↓ Price chart
when this has been cheap or pricey

↓ Forecast
where the price is heading next

↓ Statistics
all-time high & low, recent range

↑ Price alert
name your number, we'll email you

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 73 days · 73 data points (no recent data)

Historical

Generating forecast…

Price Distribution

Price distribution over 73 days • 1 price levels

Days at Price

Price Analysis

Most common price: £520 (73 days, 100.0%)

Price range: £520 - £520

Price levels: 1 different prices over 73 days

Description

This study covers the latent demand outlook for respiratory disorder treatments across the states and cities of the United States. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 12,600 cities in the United States. For each city in question, the percent share the city is of its state and of the United States as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state and city, latent demand estimates are created for respiratory disorder treatments. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of respiratory disorder treatments as including all commonly understood services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include AstraZeneca, Boehringer Ingelheim International, F. Hoffmann-La Roche, GlaxoSmithKline, Merck & Company, Mylan NV, Novartis, Sanofi, Sunovion Pharmaceuticals, Teva Pharmaceutical Industries, and Vertex Pharmaceuticals. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022).

Product Specifications

Format: paperback
ASIN: B0BLFR2JXT
Category: Books > Subjects
Domain: Amazon UK
Release Date: 26 October 2022
Listed Since: 10 November 2022

The 2023-2028 Outlook for Respiratory Disorder Treatments in the United States

It has never been this cheap. We have no record of a lower price.

Price History & Forecast

Price Distribution

Price Analysis

Description

Product Specifications

Similar Products You Might Like

The 2023-2028 Outlook for Respiratory Disorder Treatments in India

The 2023-2028 Outlook for Respiratory Disorder Treatments for US Zip Codes

The 2021-2026 World Outlook for Respiratory Care Equipment and Supplies

The 2013-2018 Outlook for Respiratory Care Equipment and Supplies in Europe

The 2013-2018 Outlook for Respiratory Care Equipment and Supplies in Latin America

The 2023-2028 World Outlook for Swine Respiratory Diseases Treatments

The 2023-2028 Outlook for Power Air Purifying Respirators in the United States

The 2025-2030 World Outlook for Swine Respiratory Diseases Treatments

The 2013-2018 Outlook for Respiratory Care Equipment and Supplies in Oceana

Technological Advances and Innovations in the Treatment of Chronic Respiratory Disorders

The 2023-2028 Outlook for Idiopathic Pulmonary Fibrosis Treatments in India

The 2023 Report on Power Air Purifying Respirators: World Market Segmentation by City

The 2023-2028 Outlook for Pulmonary Fibrosis Treatments in India

Respiratory Treatment and Prevention: 944 (Advances in Experimental Medicine and Biology)

The 2016-2021 Outlook for Incubators, Inhalators, Respirators, Resuscitators, and Other Breathing Devices Excluding Anesthetic Apparatus in the United States

The 2025-2030 World Outlook for Idiopathic Pulmonary Fibrosis Treatments

Sistema Respiratorio: Métodos, fisioterapia clínica y afecciones para fisioterapeutas

The 2016-2021 Outlook for Incubators, Inhalators, Respirators, Resuscitators, and Other Breathing Devices Excluding Anesthetic Apparatus in Japan

Breath Freshening Sprays US Outlook 2023-2028 Report

The 2023-2028 Outlook for Asthma Treatments in the United States

Respiratory Diseases

THE COMPLETE GUIDE TO RESPIRATORY CARE: All-in-one Principles to Clinical Skills, Critical Assessments, Advanced Therapeutics, And NBRC Exam Success

Respiratory System (Section 3) (American Physiological Society Handbook of Physiology)

The 2016-2021 Outlook for Incubators, Inhalators, Respirators, Resuscitators, and Other Breathing Devices Excluding Anesthetic Apparatus in Greater China